Skip to main content
Caplight Logo









Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc.

Public

Rocket Pharmaceuticals, Inc. is now publicly traded

The data on this page reflects Rocket Pharmaceuticals, Inc.'s private-market history up to the point it went public, including its funding rounds, valuation, and investors.

Last Round

Early Funding

Apr 28, 2026

Total Funding Raised

$180M

Company Overview

Rocket Pharmaceuticals, Inc. is a biotechnology company that develops a pipeline of investigational genetic therapies for rare and complex disorders.

AI Layer

Non-AI

Keywords

gene therapycell and gene therapyCGTAAV gene therapylentiviral gene therapyrare disease treatmentorphan druglate-stage biotechcardiovascular gene therapyadeno-associated virusAAVlentiviral vectorLVKRESLADIin-vivo gene therapyex-vivo gene therapygene therapy manufacturingDanon DiseaseLeukocyte Adhesion Deficiency-I

Rocket Pharmaceuticals, Inc. Comparables

Compare Rocket Pharmaceuticals, Inc. with similar companies based on industry and business-model similarity.

No public comparables are available for Rocket Pharmaceuticals, Inc.. Request access to learn about comparables coverage.

Request access

Rocket Pharmaceuticals, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early FundingApr 28, 2026

Key People

Founding team and executive leadership

Kinnari Patel

Strategic Advisor To CEO

Executive Team

Chris Stevens

Chief Operating Officer

Executive Team

Rocket Pharmaceuticals, Inc. Filings

Explore SEC and related filing metadata, where available.

Rocket Pharmaceuticals, Inc. filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Firmographic Details

Headquarters—
Employee Range228
Year Founded2015
Last FundingApr 28, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?